missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human NFRKB (aa 394-513) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (97%), Rat (97%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-52384 (PA5-52384. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
NFRKB (nuclear factor related to kappa-B-binding protein) was first identified as a factor that could bind a variant NF-kappa B site in the interleukin-2 receptor alpha (IL-2R alpha) gene. NFRKB appears to be a transcription factor central to immune cell development. Evidence of this comes from the identification of NFRKB as an amplified gene in several cases of acute myeloid leukemia. Additionally, in another clinical case, a partial deletion of the chromosomal region that includes NFRKB is shown to be associated with combined cellular immunodeficiency.
Specifications
Specifications
| Accession Number | Q6P4R8 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 4798 |
| Name | Human NFRKB (aa 394-513) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | A530090G11Rik; DNA-binding protein R kappa B; DNA-binding protein R kappa-B; INO80 complex subunit G; INO80G; NFRKB; nuclear factor related to kappa B binding protein; nuclear factor related to kappaB binding protein; nuclear factor related to kappa-B-binding protein |
| Common Name | NFRKB |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction